Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Generic Information: LuciOrfor (Laos)

Generic name: orforglipron. Brand name: LuciOrfor. Manufacturer: Lucius Pharmaceuticals (Lao) Co., Ltd. Origin: Laos. Dosage form: oral film-coated tablets, 30 tablets per box. Class: GLP-1 receptor agonist — the first oral, non-peptide, small-molecule agonist of the glucagon-like peptide-1 receptor to reach the market for weight management.

Orforglipron was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. Lilly's originator brand Foundayo was approved by the US FDA in April 2026 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. LuciOrfor is a Laos-made generic that mirrors the originator's six-step titration schedule across six strengths, from the 0.8 mg starting dose up to the 17.2 mg maximum.

What Is LuciOrfor Used For?

LuciOrfor is used together with a reduced-calorie diet and increased physical activity to help adults with obesity, or adults who are overweight and have at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia, lose excess body weight and keep it off over the long term.

Because it is an oral tablet taken once daily with no food or water restriction, it removes the needle and the rigid fasting window that older injectable or peptide-based GLP-1 therapies impose. This makes it a practical first step for patients who have avoided GLP-1 treatment because of injection anxiety or inconvenient dosing rules.

How Does LuciOrfor Work?

As a non-peptide small molecule, orforglipron binds and activates the GLP-1 receptor directly. GLP-1 is a natural hormone that regulates appetite and calorie intake. Activating its receptor in the appetite-control regions of the brain reduces hunger and food intake, while also slowing gastric emptying to prolong the feeling of fullness. The result is a meaningful and sustained reduction in body weight when combined with diet and exercise.

Unlike peptide GLP-1 drugs, a small molecule does not require cold-chain handling and can be produced by well-established chemical synthesis, which supports broader supply and more accessible pricing.

Indications

• Chronic weight management in adults with obesity (BMI ≥ 30 kg/m²)
• Chronic weight management in adults who are overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity
• Used together with a reduced-calorie diet and increased physical activity

Dosage

LuciOrfor follows the originator's six-step titration schedule to reduce gastrointestinal side effects. The starting dose is 0.8 mg once daily. After at least 30 days, the dose is increased to 2.5 mg once daily, and after a further 30 days to 5.5 mg once daily. Depending on response and tolerability, the dose can then be raised every 30 days or more through 9 mg, 14.5 mg, and up to the maximum of 17.2 mg once daily.

The tablet is swallowed whole and must not be split, crushed, or chewed. It can be taken at any time of day, with or without food, and no more than one tablet is taken per day.

Side Effects

The most common side effects are gastrointestinal and tend to occur during dose escalation: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, bloating, and fatigue. Most are mild to moderate and improve over time. Less common but serious effects to watch for include acute pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, and serious hypersensitivity reactions.

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use LuciOrfor.

Storage

Store LuciOrfor tablets at room temperature between 20°C and 25°C, with short-term excursions between 15°C and 30°C permitted. Keep the tablets in the original bottle and carton, protected from light, and out of the reach of children.

Why Choose the GLT?

As a small-molecule generic made in Laos, LuciOrfor is priced substantially below the originator Foundayo in Western markets — often by a wide margin — while carrying the same active ingredient and the same six-step titration schedule. For buyers seeking an oral GLP-1 option at a fraction of the reference-brand cost, this Laos-sourced version is a pragmatic alternative.

GLT verifies the manufacturer and registration of every shipment, and supplies full export documentation so that licensed buyers and individual patients can source with confidence.

How to Order

GLT supplies LuciOrfor (orforglipron) to licensed buyers and individual patients worldwide. To request a quotation for any of the six strengths, contact us on WhatsApp +86 15234153837 or email [email protected]. Every order is accompanied by complete documentation including Certificate of Analysis and batch traceability, with ambient shipping for oral tablets.

FAQ

Is LuciOrfor the same as Foundayo? LuciOrfor is a generic version of orforglipron, the same active ingredient as Eli Lilly's originator brand Foundayo. It follows the same six-dose titration schedule but is produced in Laos and offered at a lower price.

How many strengths does LuciOrfor come in? Six: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, each in a 30-tablet box. Patients typically start at 0.8 mg and titrate upward every 30 days or more.

Can I take LuciOrfor with food? Yes. Unlike oral semaglutide, orforglipron has no food or water restriction and can be taken at any time of day, with or without a meal.

Where can I buy orforglipron generic online? GLT supplies the Laos-made LuciOrfor internationally. Contact us on WhatsApp or email for availability and a quotation.